期刊
IMMUNOTHERAPY
卷 2, 期 1, 页码 37-56出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.09.43
关键词
dendritic cell; tumor immunotherapy; vaccination
类别
资金
- NIH [AI061684, AI071078, AI044628]
- Bill and Melinda Gates Foundation
- Doris Duke Charitable Foundation
- Cancer Research Institute
- Alliance for Lupus Research
- Emerald Foundation
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071078, R01AI061684, R37AI044628, R01AI044628] Funding Source: NIH RePORTER
The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach for harnessing the patient's own immune system to eliminate tumor cells. However, suboptimal conditions for generating potent immunostimulatory DCs, as well as the induction of tolerance and suppression mediated by the tumors and its microenvironment have contributed to limited success. Combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable anti-tumor immune responses that translate to better clinical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据